Skip to main content
Clinical Trials/NCT04918654
NCT04918654
Completed
N/A

Automatic Sound Management 3.0 in a Single-unit Audio Processor

MED-EL Elektromedizinische Geräte GesmbH1 site in 1 country20 target enrollmentJune 25, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cochlear Implants
Sponsor
MED-EL Elektromedizinische Geräte GesmbH
Enrollment
20
Locations
1
Primary Endpoint
Speech in noise
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

Cochlear implants are routine treatment for people with severe hearing loss. This study tests the RONDO 3, MED-EL's newest single-unit audio processor which comes with new features (Beamformer, Wind-Noise reduction, Ambient noise reduction, Transient noise reduction, Adaptive intelligence).

Detailed Description

MED-EL Cochlear Implants (CI) provide auditory sensations via electrical stimulation of the auditory pathways for severely to profoundly hearing-impaired individuals who obtain little or no benefit from acoustic amplification in the best aided condition. Front-end processing of acoustic signals picked up by the audio processor is routinely applied to provide optimal hearing performance under varying listening conditions. Automatic Sound Management (ASM) was introduced by MED-EL with the TEMPO+ audio processor and provided advanced compression and automatic gain management. With the SONNET audio processor, MED-EL introduced ASM 2.0, which added wind noise reduction and microphone directionality to the front-end processing. With the SONNET 2 audio processor, ASM 3.0 was implemented and the features ambient noise reduction, transient noise reduction and an adaptive intelligence (AI) were added. The RONDO 3 implements now ASM 3.0. This study investigates the impact of ASM 3.0 as implemented in the RONDO 3 on CI users' speech performance and their subjective quality of hearing.

Registry
clinicaltrials.gov
Start Date
June 25, 2021
End Date
December 11, 2023
Last Updated
5 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
MED-EL Elektromedizinische Geräte GesmbH
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A minimum of 18 years old
  • Experienced user of a RONDO 3 (≥ 3 months) for the ear to be tested
  • Post-lingual onset of severe to profound sensory-neural hearing loss on the ear to be tested
  • A minimum of 40% speech recognition in the Freiburg Monosyllables Test in quiet at 65 dB SPL for the ear to be tested (at the last time tested in clinical routine)
  • Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure.
  • Exclusion criteria
  • Lack of compliance with any inclusion criteria
  • CI user with contralateral hearing equal to or better than 30 dB (pure-tone average over the following frequencies: 250, 500, 1000, and 2000 Hz)
  • Implanted with C40X, or C40C on the ear to be tested
  • Implanted with an Auditory Brainstem Implant (ABI) or split electrode array

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Speech in noise

Time Frame: Baseline

Oldenburg Sentence Test in noise (S0 N±90 N180)

Secondary Outcomes

  • User Satisfaction(Baseline)
  • Speech in noise(Baseline)
  • Quality of Hearing(Baseline)
  • Device Satisfaction(Baseline)

Study Sites (1)

Loading locations...

Similar Trials